Thomas Reiberger's research while affiliated with University of Vienna and other places

Publications (620)

Article
Full-text available
Impaired response to COVID-19 vaccination is of particular concern in immunosuppressed patients. To determine the best vaccination strategy for this vulnerable group we performed a single center, 1:1 randomized blinded clinical trial. Patients who failed to seroconvert upon two mRNA vaccinations (BNT162b2 or mRNA-1273) are randomized to receive eit...
Article
Full-text available
LINKED CONTENT This article is linked to Jachs et al papers. To view these articles, visit https://doi.org/10.1111/apt.16945 and https://doi.org/10.1111/apt.16115
Article
Background & Aims Non-invasive tests (NIT)s for clinically significant portal hypertension (CSPH; hepatic venous pressure gradient [HVPG] ≥10mmHg) have predominantly been studied in patients with active HCV-infection. Investigations after HCV-cure are limited and yielded conflicting results. We conducted a pooled analysis to determine the diagnosti...
Article
The COVID‐19 pandemic necessitates healthcare restrictions that also affected ongoing hepatitis C virus (HCV) elimination efforts. We assessed the value of a physician‐operated HCV hotline on treatment and cure rates throughout the pandemic. All HCV patients undergoing HCV therapy at the Vienna General Hospital from 2019 to 2021 were included. An H...
Article
Background & Aims Hypercoagulability and hypofibrinolysis in acutely decompensated cirrhosis (AD) may be implicated in disease progression and hemostatic complications. We conducted a prospective study to: [1] characterize hemostatic alterations in AD; [2] evaluate whether such alterations can predict ACLF and bleeding/thrombosis. Methods Hospital...
Article
Background Using direct acting antivirals (DAA) for recently acquired hepatitis C virus (RAHCV-) infections, particularly in HIV-positive men having sex with men (MSM), dramatically reduced hepatitis C incidence. However, implementation into clinical practice is challenging. The aim of this study was to analyse spontaneous clearance (SC) rates of R...
Article
Full-text available
Hypoalbuminemia (HA) is frequently observed in systemic inflammatory diseases and in liver disease. However, the influence of HA on the pharmacokinetics and toxicity of compounds with high plasma albumin binding remained insufficiently studied. The ‘ lack-of-delivery-concept ’ postulates that HA leads to less carrier mediated uptake of albumin boun...
Article
Full-text available
Background &aims: Alpha-1 antitrypsin (AAT) deficiency causes/predisposes for advanced chronic liver disease (ACLD). However, the role of the SERPINA1 Pi*Z allele in patients who have already progressed to ACLD is unclear. Thus, we aimed to evaluate the impact of the Pi*Z allele on the requirement of liver transplantation/liver-related death in ACL...
Article
Full-text available
Background & aims: Experimental evidence indicates that systemic inflammation (SI) promotes liver fibrogenesis. This study investigated the potential link between SI and fibrogenesis in patients with advanced chronic liver disease (ACLD). Methods: Serum biomarkers of SI (CRP, IL-6, procalcitonin [PCT]) and extracellular matrix (ECM) turnover (i....
Article
Background and Aims Carvedilol induces stronger decreases in hepatic venous pressure gradient (HVPG) than conventional nonselective beta-blockers (NSBB), i.e., propranolol. Limited data exists on the efficacy of carvedilol in secondary prophylaxis of variceal bleeding. Methods Patients undergoing paired HVPG measurements for guiding secondary prop...
Article
Full-text available
Background Bulevirtide (BLV) blocks the uptake of the hepatitis D virus (HDV) into hepatocytes via the sodium/bile acid cotransporter NTCP. BLV was conditionally approved by the EMA but real‐life data on BLV efficacy are limited. Methods Patients were treated with BLV monotherapy. Patients who did not achieve further decreases in HDV‐RNA after 24...
Article
Full-text available
Nonselective beta-blockers are used as prophylaxis for variceal bleeding in patients with advanced chronic liver disease (ACLD). The acute hemodynamic response to intravenous propranolol (i.e., ≥10% reduction in hepatic venous pressure gradient [HVPG]) is linked to a decreased risk of variceal bleeding. In this study, we aimed to investigate the ov...
Article
Background Von Willebrand factor antigen (VWF) is a non-invasive marker for clinically significant portal hypertension (HVPG≥10 mmHg) and confers HVPG-independent prognostic information. While quantification of increased VWF-levels is not relevant in the context of von Willebrand disease, highly elevated VWF may be of clinical significance in ACLD....
Article
Full-text available
Objective Hepatocellular carcinoma (HCC) often develops in patients with alcohol-related cirrhosis at an annual risk of up to 2.5%. Some host genetic risk factors have been identified but do not account for the majority of the variance in occurrence. This study aimed to identify novel susceptibility loci for the development of HCC in people with al...
Article
The introduction of Hepatitis B Immunoglobulins (HBIg) prophylaxis at and after liver transplantation (LT) facilitated excellent long‐term survival of transplant patients with chronic hepatitis B virus (HBV) infection. Several studies suggested that only short‐term (i.e. 4‐8 weeks of) HBIg prophylaxis after LT followed by long‐term administration o...
Article
Full-text available
Background & Aims: Although ascites is the most frequent first decompensating event in cirrhosis, the clinical course after ascites as the single index decompensation is not well defined. The aim of this multicentre study was thus to systematically investigate the incidence and type of further decompensation after ascites as the first decompensatin...
Article
Full-text available
Background: Cholestasis is associated with disease severity and worse outcome in coronavirus disease of 2019 (COVID-19). Cases of secondary sclerosing cholangitis (SSC) after severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection have been described. Methods: Hospitalized patients with COVID-19 between 03/2020 and 07/2021 were in...
Article
Background and Aims Direct oral anticoagulants (DOACs) may simplify management of Budd-Chiari Syndrome (BCS). Here we report our experience with off-label use of DOACs for anticoagulation in BCS. Methods Safety of DOAC vs. vitamin K antagonist (VKA) treatment as well as associated clinical outcomes were retrospectively assessed in 47 BCS patients...
Article
Full-text available
Background & Aims Functional Liver Imaging Score (FLIS) derived from gadoxetic acid (GA)-enhanced MRI correlates with liver function in chronic liver disease (CLD) patients and independently predicts liver-related mortality. Splenic craniocaudal diameter (SCCD) is a marker of portal hypertension, a key driver of disease progression. The aim of this...
Article
Full-text available
Background and aims: The coronavirus disease of 2019 (COVID-19) causes considerable mortality worldwide. We aimed to investigate the frequency and predictive role of abnormal liver chemistries in different age groups. Methods: Patients with positive severe acute respiratory distress syndrome-coronavirus-2 (SARS-CoV-2) polymerase chain reaction (...
Article
Background Portal hypertension (PH) does not resolve in a considerable proportion of patients who achieved HCV-cure. Aims To investigate (i)whether HCV-cure impacts cytokines that orchestrate angiogenesis (i.e.,Ang1/Ang2/VEGF) and fibrogenesis (i.e.,PDGF/TGF-β) and (ii)whether their changes reflect PH-evolution and its complications. Methods We m...
Article
Full-text available
Background Patients with cirrhosis often develop portal hypertension-associated splenomegaly and hypersplenism, potentially causing severe cytopenia. AIMS Systematic assessment on the impact of transjugular intrahepatic portosystemic shunt (TIPS) implantation on platelet count (PLT), hemoglobin (Hb), and white blood cell count (WBC). Methods Pati...
Article
Full-text available
The recently reported epidemic of acute hepatitis C virus (HCV) infections (AHC)—observed predominantly among men who have sex with men (MSM)—may now decline due to wide availability of direct‐acting antivirals (DAAs). This study aimed to investigate the current trends of acute hepatitis C in Vienna. Patients presenting with acute hepatitis C betwe...
Article
Purpose Portal hypertension (PH)-associated splenomegaly is caused by portal venous congestion and splanchnic hyperemia. This can trigger hypersplenism, which favors the development of cytopenia. We investigated the time-dependent impact of splenectomy on portal pressure and blood cell counts in animal models of non-cirrhotic and cirrhotic PH. Mat...
Article
Full-text available
Background: Since nonalcoholic fatty liver disease (NAFLD) has become the leading cause of liver disease in the Western world, clinicians need reliable noninvasive tools for the identification of NAFLD-associated fibrosis. Limited evidence on the performance of the novel shear wave elastography technique Elast-PQ (EPQ) in NAFLD is available. Meth...
Article
Full-text available
Background: Nucleos(t)ide analog (NA) treatment for hepatitis B virus (HBV) infection may improve clinically significant portal hypertension (CSPH). Data on hepatic venous pressure gradient (HVPG) and non-invasive tests (NITs) for risk re-stratification in virally suppressed HBV-infected patients with pre-treatment CSPH are limited. Methods: We...
Article
Background&aims It has been suggested that the ratio of procoagulant factor VIII to anticoagulant protein C (FVIII/PC) reflects the haemostatic equilibrium. Moreover, FVIII/PC predicted decompensation/death in a small study not accounting for portal hypertension severity. We investigated (i) the prognostic value of FVIII/PC (outcome-cohort) and (ii...
Article
Full-text available
Background The impact of changes in portal pressure before and after liver resection (defined as ΔHVPG) on postoperative kidney function remains unknown. Therefore, we investigated the effect of ΔHVPG on (i) the incidence of postoperative AKI and (ii) the renin-angiotensin system (RAAS) and sympathetic nervous system (SNS) activity. Methods We inc...
Article
Cirrhotic patients have an increased risk of bleeding and thromboembolic events, with platelets being involved as key players in both situations. The impact of peripheral versus central blood sampling on platelet activation remains unclear. In 33 cirrhotic patients, we thus analyzed platelet function in peripheral (P) and central (C) blood samples....
Article
Full-text available
The host genetic background for hepatocellular carcinoma (HCC) is incompletely understood. We aimed to determine if four germline genetic polymorphisms, rs429358 in apolipoprotein E (APOE), rs2642438 in mitochondrial amidoxime reducing component 1 (MARC1), rs2792751 in glycerol‐3‐phosphate acyltransferase (GPAM), and rs187429064 in transmembrane 6...
Article
Full-text available
Patients with compensated advanced chronic liver disease who develop clinically significant portal hypertension (CSPH) are at high risk for hepatic decompensation and mortality if left untreated. Liver biopsy and hepatic venous pressure gradient (HVPG) measurements are the current gold standard procedures for determining fibrosis severity and diagn...
Article
Full-text available
Background Primary biliary cholangitis (PBC) may progress to cirrhosis and clinically significant portal hypertension (CSPH). This study assesses different features of CSPH and their distinct prognostic impact regarding decompensation and survival in patients with PBC. Methods Patients with PBC were identified during a database query of our digita...
Article
To expand on the work of previous meetings, a virtual Baveno VII workshop was organised for October 2021. Among patients with compensated cirrhosis or compensated advanced chronic liver disease (cACLD - defined at the Baveno VI conference), the presence or absence of clinically significant portal hypertension (CSPH) is associated with differing out...